1. Home
  2. FNWD vs SCLX Comparison

FNWD vs SCLX Comparison

Compare FNWD & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FNWD
  • SCLX
  • Stock Information
  • Founded
  • FNWD 1994
  • SCLX 2011
  • Country
  • FNWD United States
  • SCLX United States
  • Employees
  • FNWD N/A
  • SCLX N/A
  • Industry
  • FNWD Savings Institutions
  • SCLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FNWD Finance
  • SCLX Health Care
  • Exchange
  • FNWD Nasdaq
  • SCLX Nasdaq
  • Market Cap
  • FNWD 137.4M
  • SCLX 143.6M
  • IPO Year
  • FNWD N/A
  • SCLX N/A
  • Fundamental
  • Price
  • FNWD $31.10
  • SCLX $0.99
  • Analyst Decision
  • FNWD
  • SCLX Strong Buy
  • Analyst Count
  • FNWD 0
  • SCLX 3
  • Target Price
  • FNWD N/A
  • SCLX $11.33
  • AVG Volume (30 Days)
  • FNWD 2.9K
  • SCLX 184.3K
  • Earning Date
  • FNWD 10-29-2024
  • SCLX 11-12-2024
  • Dividend Yield
  • FNWD 1.54%
  • SCLX N/A
  • EPS Growth
  • FNWD N/A
  • SCLX N/A
  • EPS
  • FNWD 3.07
  • SCLX N/A
  • Revenue
  • FNWD $70,040,000.00
  • SCLX $50,833,000.00
  • Revenue This Year
  • FNWD N/A
  • SCLX $34.42
  • Revenue Next Year
  • FNWD N/A
  • SCLX $12.77
  • P/E Ratio
  • FNWD $10.14
  • SCLX N/A
  • Revenue Growth
  • FNWD N/A
  • SCLX 9.41
  • 52 Week Low
  • FNWD $17.29
  • SCLX $0.73
  • 52 Week High
  • FNWD $33.05
  • SCLX $2.63
  • Technical
  • Relative Strength Index (RSI)
  • FNWD 53.65
  • SCLX 57.77
  • Support Level
  • FNWD $30.51
  • SCLX $0.77
  • Resistance Level
  • FNWD $31.40
  • SCLX $1.13
  • Average True Range (ATR)
  • FNWD 0.47
  • SCLX 0.11
  • MACD
  • FNWD -0.23
  • SCLX 0.03
  • Stochastic Oscillator
  • FNWD 23.90
  • SCLX 70.75

About FNWD Finward Bancorp

Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: